Bristol Myers Squibb shared a post on LinkedIn:
“We are excited to announce a new collaboration with Microsoft, a leader in AI-powered radiology and clinical workflow technologies, to help accelerate the early detection of lung cancer.
Lung cancer remains the leading cause of cancer-related deaths in the United States, with medically underserved populations experiencing disproportionately higher mortality rates. This collaboration focuses on expanding early detection and equitable access to care through lung cancer-specific AI workflows on Microsoft’s suite of radiology solutions. These tools can help detect lung nodules earlier, flag potential abnormalities, and guide patients to appropriate care.
By partnering across the technology and healthcare ecosystem, we are helping to bring leading capabilities to market and meaningfully improve the patient journey.”
Nathan Pennell, SVP and Head of Global Medical Oncology at Bristol Myers Squibb, shared this post, adding:
“Very proud to see Bristol Myers Squibb wading into this area where there is such a large unmet need. As exciting as our treatments are in more advanced disease, the fact remains that the biggest impact on lung cancer survival would be in prevention and early detection to cure people at the earliest stages!”
More posts about Bristol Myers Squibb.